Perceptive Xontogeny Venture Fund
Perceptive Xontogeny Venture Fund (PXV) is an early-stage life sciences venture capital fund, managed as a partnership between Perceptive Advisors and Xontogeny. The fund targets investments in biotechnology, drug discovery, and healthcare technologies, primarily leading Series A and select Series B financings.
52% of their portfolio is in Biotech & Life Sciences. Deal activity increased 600% year-over-year (7 deals in the last 12 months). Average disclosed round size is $100.5M (across 21 rounds with reported amounts).
Portfolio
19
Fund Size
$515M
Top Stage
Series A
Last 12 Mo
6
Team
Bill Schwieterman, MD
Managing Director, Regulatory
David Ingraldi
Managing Director, Investor Relations & Marketing
Fred Callori
Managing Director
Sean Mansoory
Managing Director
Sean Nelson
Managing Director & Head of Wealth
Craig Yeshion, MD
Director of Research
David Kim
Tax Director
Patrick Morrow
Director of Investor Relations & Marketing
Kriti Lall
Principal, Biotechnology
Andrés Horcajo
Vice President, Investor Relations & Marketing
Carlos Vazquez
Vice President
Emerson Shiu
Vice President, Medical Devices/Diagnostics/MedTech
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Merida Biosciences | Series A | $121M | Aug 2026 |
| CCrystalys Therapeutics Inc | Series B | $130M | Jul 2026 |
| CCereVasc, Inc. | Series C | $85M | Jun 2026 |
| CCereVasc, Inc. | Series C | $85M | Jan 2026 |
 Crystalys | Series A | $205M | Sep 2025 |
| CCrystalys Therapeutics Inc | Series A | $205M | Sep 2025 |
 Galvanize Therapeutics | Series C | $100M | Sep 2025 |
 Mercy BioAnalytics | Series B | $59M | Sep 2025 |
| MMercy Bio | Series B | $59M | Sep 2025 |
 Avalyn Pharma, Inc. | Series D | $100M | Jul 2025 |
 Zucara Therapeutics | Series B | $25M | May 2025 |
 Cerevasc | Series B | $70M | May 2024 |
| AAdaptilens | Series A | $17.5M | Apr 2024 |
 Avalyn Pharma | Series C | $175M | Sep 2023 |
 CARGO Therapeutics | Series A | $200M | Mar 2023 |
| AAvenge Bio | Series A | — | Jan 2022 |
 Vivosense | Series A | $25M | Jan 2022 |
| AAvengebio | Series A | $45M | Jan 2022 |
 Marea Therapeutics | Series A | $190M | — |
| Marea Therapeutics | Series B | — | — |
 A-Alpha Bio | Seed | $22.4M | — |
 SURF BIO | Seed | $16M | — |
| Avalyn Pharma, Inc. | Series C | $175M | — |
Top Co-Investors
Last updated: 9 September 2026